Simon Sturge left the role of Director at MoonLake Immunotherapeutics, effective February 28, 2026. As of November 14, 2026, MoonLake Immunotherapeutics has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from February 23, 2026 to June 9, 2026, naming 1 departure (Form 8-K, February 23, 2026).
29 companies changed executives this week, 1 had other signals.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| ONITY GROUP INC. | announced the departure of its Chief Investment Officer | |
| Adicet Bio, Inc. | announced the departure of its Director | |
| MAMMOTH ENERGY SERVICES, INC. | announced the departure of its Chief Operating Officer | |
| CERENOME, INC. | named a new Director | |
| Cohen & Co Inc. | named a new Chief Executive Officer |
Sell to companies like MoonLake Immunotherapeutics? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
MoonLake Immunotherapeutics reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-02-23 to 2026-06-09. They name 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as MoonLake Immunotherapeutics files it.
Also on the record for MoonLake Immunotherapeutics
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| August 14, 2026 | Stake report, Schedule 13G, by T. Rowe Price Investment Management, Inc. | 5.3% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by Cormorant Asset Management, LP | 4.35% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by Deep Track Capital, LP | 9.74% of the class | 5%+ stakes | Source |
| June 29, 2026 | Stake report, Schedule 13D/A, by BIOTECHNOLOGY VALUE FUND L P | 19.7% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by Cormorant Asset Management, LP | 6.25% of the class | 5%+ stakes | Source |
| April 2, 2026 | Stake report, Schedule 13D/A, by BIOTECHNOLOGY VALUE FUND L P | 22.3% of the class | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G, by Cormorant Asset Management, LP | 6.1% of the class | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G/A, by Avoro Capital Advisors LLC | 3.15% of the class | 5%+ stakes | Source |
| November 12, 2025 | Stake report, Schedule 13G, by Deep Track Capital, LP | 6.46% of the class | 5%+ stakes | Source |
| November 10, 2025 | Stake report, Schedule 13D/A, by BIOTECHNOLOGY VALUE FUND L P | 27.7% of the class | 5%+ stakes | Source |
| November 5, 2025 | Stake report, Schedule 13G/A, by FMR LLC | 1.1% of the class | 5%+ stakes | Source |
| October 1, 2025 | Stake report, Schedule 13G/A, by Chen Bihua | 3.14% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs MoonLake Immunotherapeutics now and the warning signs.
Free to see. No signup.
Keep reading
More on MoonLake Immunotherapeutics and the records around it.
MoonLake Immunotherapeutics elsewhere on the record
- 5%+ stake filings Aug 2026
- Who owns it
Companies that share a holder
- Chen Bihua also filed stake reports on 1 other company: BridgeBio Oncology Therapeutics, Inc. (Jul 2026)
- Cormorant Asset Management, LP also filed stake reports on 17 other companies: Corbus Pharmaceuticals Holdings, Inc. (Nov 2026), Adlai Nortye Ltd. (Aug 2026), BioAge Labs, Inc. (Aug 2026)
- Avoro Capital Advisors LLC also filed stake reports on 18 other companies: Arrowhead Pharmaceuticals, Inc. (Aug 2026), Avalo Therapeutics, Inc. (Aug 2026), Hemab Therapeutics Holdings, Inc. (Aug 2026)
Watch MoonLake Immunotherapeutics
Get an email when MoonLake Immunotherapeutics files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on MoonLake Immunotherapeutics?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on MoonLake Immunotherapeutics: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on MoonLake Immunotherapeutics covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
14 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 14 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-06-09 | Reported | not named in the filing | 8-K, 2026-06-09 | ||
| 2026-02-23 | Out | Director | 2026-02-28 | 8-K, 2026-02-23 |
Why did they leave? What the filings say
For each named departure below, the sentence from the company's own filing that gives a reason, word for word. Where a filing gives none, it says so here; nothing is inferred.
- Simon Sturge, Director (filed 2026-02-23):
Mr. Sturge's decision to resign from the Board was not the result of any dispute or disagreement with the Company on any matter relating to the Company's operations, policies or practices.
Who leads MoonLake Immunotherapeutics, as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Director: Simon Sturge, departure reported, effective 2026-02-28 (filed 2026-02-23). No successor is named in these filings.
New leaders reset buying decisions — get the Full Report on MoonLake Immunotherapeutics: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Director at MoonLake Immunotherapeutics, with the record behind each one.
Find candidates like Director at MoonLake ImmunotherapeuticsEvery change, in the filing's words
Reported
Departure of Director or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
- At the Annual Meeting, the Company's shareholders approved an amendment and restatement of the Company's 2022 Equity Incentive Plan (as so amended, the "Plan") to increase the number of Class A Ordinary Shares available for stock-based awards by 5,000,000 shares, remove liberal share recycling provisions, incorporate a one-year minimum vesting requirement, revise the non-employee director compensation limits set forth therein, specify the treatment of outstanding awards in the event of a change in control, extend the term of the Plan to June 4, 2036 and make certain other administrative changes.
Departing: Simon Sturge, Director, effective 2026-02-28
On February 18, 2026, Simon Sturge notified the Board of Directors (the "Board") of the Company of his intent to resign as a member of the Board, effective as of February 28, 2026 (the "Effective Date").
- As of the Effective Date, the size of the Board will be reduced from six to five directors.
- The Company and the Board extend their deepest gratitude to Mr. Sturge for his contributions to the Company.
- In connection with Mr. Sturge's resignation, Dr. Jorge Santos da Silva was appointed Interim Chair of the Board, and Spike Loy was appointed as Lead Independent Director, both effective as of the Effective Date.
Tools for this story
Each opens in a new tab, filled in for MoonLake Immunotherapeutics. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.
